Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7194MR)

This product GTTS-WQ7194MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7194MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9789MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ15358MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ10483MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ3476MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ2821MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ850MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ11271MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ2937MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG888
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW